 I. To determine the recommended phase II dose of topical bexarotene 1 weight by weight ww gel for evaluation in healthy women. Dose Escalation Group II. Conduct an intervention of topical 1 bexarotene gel to an unaffected breast of healthy women at high risk for breast cancer for 4 weeks at the maximum tolerated dose MTD as determined during the dose escalation group phase to assess bexarotene concentration in the breast tissue. Dose Expansion Group 